194 related articles for article (PubMed ID: 31924838)
1. Germline polymorphisms in the Von Hippel-Lindau and Hypoxia-inducible factor 1-alpha genes, gene-environment and gene-gene interactions and renal cell cancer.
van de Pol JAA; van den Brandt PA; van Engeland M; Godschalk RWL; van Schooten FJ; Hogervorst JGF; Schouten LJ
Sci Rep; 2020 Jan; 10(1):137. PubMed ID: 31924838
[TBL] [Abstract][Full Text] [Related]
2. The polymorphisms in the VHL and HIF1A genes are associated with the prognosis but not the development of renal cell carcinoma.
Qin C; Cao Q; Ju X; Wang M; Meng X; Zhu J; Yan F; Li P; Ding Q; Chen J; Gu M; Zhang W; Yin C; Zhang Z
Ann Oncol; 2012 Apr; 23(4):981-9. PubMed ID: 21778301
[TBL] [Abstract][Full Text] [Related]
3. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
Moore LE; Nickerson ML; Brennan P; Toro JR; Jaeger E; Rinsky J; Han SS; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Schmidt LS; Lenz P; Karami S; Linehan WM; Merino M; Chanock S; Boffetta P; Chow WH; Waldman FM; Rothman N
PLoS Genet; 2011 Oct; 7(10):e1002312. PubMed ID: 22022277
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors.
Verbiest A; Lambrechts D; Van Brussel T; Couchy G; Wozniak A; Méjean A; Lerut E; Oudard S; Verkarre V; Job S; de Reynies A; Machiels JP; Patard JJ; Zucman-Rossi J; Beuselinck B
Clin Genitourin Cancer; 2018 Aug; 16(4):266-273. PubMed ID: 29503246
[TBL] [Abstract][Full Text] [Related]
5. Does the VHL polymorphisms rs779805 and rs1642742 affect renal cell carcinoma susceptibility, prognosis and survival in Central European population?
Chrabańska M; Szweda-Gandor N; Drozdzowska B
Medicine (Baltimore); 2023 Dec; 102(50):e36540. PubMed ID: 38115281
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA target site polymorphisms in the VHL-HIF1α pathway predict renal cell carcinoma risk.
Wei H; Ke HL; Lin J; Shete S; Wood CG; Hildebrandt MA
Mol Carcinog; 2014 Jan; 53(1):1-7. PubMed ID: 22517515
[TBL] [Abstract][Full Text] [Related]
7. Alcohol consumption and mutations or promoter hypermethylation of the von Hippel-Lindau gene in renal cell carcinoma.
Schouten LJ; van Dijk BA; Oosterwijk E; van Engeland M; Hulsbergen-van de Kaa CA; Kiemeney LA; Goldbohm RA; Kester A; de Vogel S; Schalken JA; van den Brandt PA
Cancer Epidemiol Biomarkers Prev; 2008 Dec; 17(12):3543-50. PubMed ID: 19064569
[TBL] [Abstract][Full Text] [Related]
8. VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma.
Lessi F; Mazzanti CM; Tomei S; Di Cristofano C; Minervini A; Menicagli M; Apollo A; Masieri L; Collecchi P; Minervini R; Carini M; Bevilacqua G
Med Oncol; 2014 Mar; 31(3):840. PubMed ID: 24446253
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
10. Two Single Nucleotide Polymorphisms in the Von Hippel-Lindau Tumor Suppressor Gene in Patients with Clear Cell Renal Cell Carcinoma.
Chrabańska M; Szweda-Gandor N; Drozdzowska B
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835190
[TBL] [Abstract][Full Text] [Related]
11. Renal cell carcinoma risk is associated with the interactions of APOE, VHL and MTHFR gene polymorphisms.
Lv C; Bai Z; Liu Z; Luo P; Zhang J
Int J Clin Exp Pathol; 2015; 8(5):5781-6. PubMed ID: 26191297
[TBL] [Abstract][Full Text] [Related]
12. Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.
Khaliq S; Ajaz S; Firasat S; Shahid S; Hasan AS; Sultan G; Mohsin R; Hashmi A; Mubarak M; Naqvi SA; Rizvi SA; Mehdi SQ; Abid A
Mutat Res; 2014; 763-764():45-52. PubMed ID: 24727139
[TBL] [Abstract][Full Text] [Related]
13. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
[TBL] [Abstract][Full Text] [Related]
14. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
15. Hypertension, antihypertensives and mutations in the Von Hippel-Lindau gene in renal cell carcinoma: results from the Netherlands Cohort Study.
Schouten LJ; van Dijk BA; Oosterwijk E; Hulsbergen-van de Kaa CA; Kiemeney LA; Goldbohm RA; Schalken JA; van den Brandt PA
J Hypertens; 2005 Nov; 23(11):1997-2004. PubMed ID: 16208141
[TBL] [Abstract][Full Text] [Related]
16. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.
Smits KM; Schouten LJ; van Dijk BA; Hulsbergen-van de Kaa CA; Wouters KA; Oosterwijk E; van Engeland M; van den Brandt PA
Clin Cancer Res; 2008 Feb; 14(3):782-7. PubMed ID: 18245539
[TBL] [Abstract][Full Text] [Related]
17. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
[TBL] [Abstract][Full Text] [Related]
18. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
19. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
20. Loss of Von Hippel-Lindau (
Kim H; Shim BY; Lee SJ; Lee JY; Lee HJ; Kim IH
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
